Get started
Author

Gopinath M. Ranganna

Observed names: G. Ranganna, GOPINATH RANGANNA, Gopinath Ranganna, Ranganna, Gopinath
Institution: Viatris
ORCID: 0000-0001-9974-3354
Observed ORCID: 0000-0001-9974-3354
OpenAlex ID: A5086610054
The Path Towards a Tailored Clinical Biosimilar Development
2020 · Martin Schiestl, Gopinath Ranganna, et al. · BioDrugs · 75
PDF
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim
2018 · Cornelius F. Waller, Renger G. Tiessen, et al. · Journal of Cancer Research and Clinical Oncology · 33
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
2019 · Cornelius F. Waller, Gopinath M. Ranganna, et al. · Annals of Hematology · 26
PDF
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
2021 · Ulrike Hövelmann, Yaron Raiter, et al. · Diabetes Obesity and Metabolism · 13
PDF
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
2022 · Thomas C. Blevins, Yaron Raiter, et al. · BioDrugs · 10
PDF
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
2021 · Mark A. Socinski, Cornelius F. Waller, et al. · Therapeutic Advances in Medical Oncology · 10
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability
2025 · Sarika Deodhar, Subramanian Loganathan, et al. · Advances in Therapy · 5
PDF
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer
2023 · Joel S. Owen, Russell J. Rackley, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 3
Henoch–Schonlein Purpura with thrombocythaemia: an abnormality in Smad4 expression?
2008 · Joshua M. Brostoff, Gopinath M. Ranganna, et al. · Rheumatology International · 3
1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)
2020 · M.A. Socinski, C. Waller, et al. · Annals of Oncology · 2
Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H.
2018 · Praveen Kallamvalliillam Sankaran, Dinesh V. Palanivelu, et al. · Journal of Clinical Oncology · 2
Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
2021 · Joerg Putzke, Scott Haughie, et al. · BioDrugs · 1
PDF
Author response for "Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study"
2021 · Ulrike Hövelmann, Yaron Raiter, et al. · Publons reviews and discussion
728-P: Mylan Insulin Aspart (MYL-1601D) Is Bioequivalent to Novolog (U.S.-Licensed Insulin Aspart) and NovoRapid (EU-Approved Insulin Aspart)
2021 · YARON RAITER, ULRIKE HÖVELMANN, et al. · Diabetes
729-P: Efficacy and Safety of Mylan Insulin Glargine Products (MYL-1501D) from Two Manufacturing Processes (Process V and Process VI) in Combination with Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
2021 · YARON RAITER, THOMAS BLEVINS, et al. · Diabetes
741-P: Efficacy and Safety of MYL-1601D (Mylan's Insulin Aspart) Compared with Novolog (Novo Nordisk's Insulin Aspart) in Patients with Type 1 Diabetes (T1DM) after 24 Weeks
2021 · YARON RAITER, THOMAS BLEVINS, et al. · Diabetes
Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC).
2021 · Joel Owen, Russell J. Rackley, et al. · Journal of Clinical Oncology
SAT0260 Biomarkers Associated with Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate with Changes in Clinical Response in Subjects Treated with Mavrilimumab at Doses above 10 Mg
2014 · W. White, P.C. Ryan, et al. · Annals of the Rheumatic Diseases
FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study
2013 · G. Burmester, T. Takeuchi, et al. · Annals of the Rheumatic Diseases
Works count: 21
Citation count: 183
H-index: 6
I10-index: 6
Year
Topic
Type